Pathway Medical Technologies Names Paul Buckman Chairman of the Board of...(es for the treatment of arterial disease...)

Date:3/6/2008

es for the treatment of arterial disease. The company's initial focus is treating peripheral arterial disease (PAD) more quickly, safely and effectively than existing technologies. An estimated 8-12 million people are afflicted by PAD in the U.S., and that number is projected to grow to over 20 million during the next 10 years. The company's Pathway PV(TM) Atherectomy System allows for a minimally invasive procedure designed to restore circulation in the peripheral arteries by removing both hard and soft diseased tissue. For further information, visit the company's Web site at http://www.pathwaymedical.com.

'/>"/>

SOURCE Pathway Medical Technologies, Inc. Copyright©2008 PR Newswire. All rights reserved

0 GOOD

Page: 1 2
Related biology technology :

1. Genetic pathway critical to disease, aging found
2. AspenBio Pharma Pursues FDA 510(k) Application Pathway for Appendicitis Blood Test
3. Pathway Diagnostics Announces Patent Issuance for the Diagnostic Measurement of HIV Tropism for the Initiation or Modification of HIV Therapy
4. Novocell Announces Discovery Linking Key Cancer Cell Signaling Pathways With Proliferation and Self-Renewal of Human Embryonic Stem Cells
5. Systems Medicine (SM), a Subsidiary of Cell Therapeutics, Inc. (CTI), Announces Execution of CRADA with NCI/NIH to Develop Potential Cancer Treatments Targeting the Insulin Growth Factor (IGF) Pathway
6. Pathway Medical Technologies Adds Joe Rafferty as VP, Sales, and Moves To Larger Facility to Accommodate Rapid Growth
7. Major Medical Journal Reports Higher Success, Fewer Complications and Lower Cost Treating DVT With Trellis(R) Isolated Thrombolysis Compared With Catheter-Directed Thrombolysis
8. Vista Partners Updates Coverage on Inovio Biomedical Corporation (Amex: INO) With $3.52 Price Target
9. LifeNet Health(R) Unveils New Biomedical Spine Implant
10. IMPAC Medical Systems and Aperio to Develop Integrated Solution for Anatomic Pathology
11. M. Scott Harris, M.D., Joins Ocera Therapeutics, Inc., as Chief Medical Officer